Money is moving into cannabis stocks at a pace this sector hasn't seen in years, and the numbers back that up. The AdvisorShares Pure US Cannabis ETF (MSOS) posted a 103.7% one-year net asset value return as of May 31, more than double the North American Marijuana Index's 36.9% gain and well ahead of the S&P 500's 29.8%. Over just the past three months, MSOS climbed 28% while the broader marijuana benchmark actually slipped about 1% - a divergence that tells you this rally is concentrated, not universal.

What's driving the concentration is a mix of regulatory catalysts and one very symbolic listing. Trulieve Cannabis, which makes up roughly 30% of MSOS assets, began trading on the New York Stock Exchange under the ticker TRLV this week. That's not a small operational detail for multi-state operators watching from the sidelines. Uplisting to a senior exchange typically requires a company to restructure its business - in Trulieve's case, separating medical cannabis operations from adult-use lines - and it opens doors to institutional capital that Nasdaq's OTC-style venues can't match. For dispensary operators in emerging medical markets, the mechanics behind this shift matter as much as the headline; states building out regulatory infrastructure, including newer medical programs, increasingly lean on established retail marijuana software maine operators use for compliance tracking, inventory management and point-of-sale reporting, since capital markets access ultimately depends on clean operational records. retail marijuana software maine

The DEA Hearing Everyone's Watching

Here's the actual event underpinning all this investor enthusiasm: a DEA administrative hearing scheduled for June 29, expected to run through no later than July 15, will examine whether cannabis - including adult-use products, not just medical - should move to Schedule III. That's a meaningfully bigger question than what happened in April, when Acting Attorney General Todd Blanche moved state-licensed medical marijuana into Schedule III and kicked off the broader rescheduling process. The April action already eliminated a major tax headache: licensed medical operators no longer face the harshest effects of Section 280E, the federal tax code provision that has long blocked cannabis companies from deducting ordinary business expenses like payroll and rent because the plant remains federally controlled.

President Trump's move to formally nominate Blanche as permanent attorney general adds another layer of certainty investors seem to be pricing in. Fair enough - continuity at the top of DOJ reduces the odds of the rescheduling process stalling out. But a hearing is still a hearing, not a finished rule. Administrative proceedings can extend, get appealed, or produce narrower outcomes than markets expect. Operators betting balance-sheet decisions on a favorable ruling are taking a real regulatory risk, not a formality.

What Rescheduling Would Actually Change for Operators

If adult-use cannabis moves to Schedule III, the operational implications go well beyond stock prices. Full 280E relief would let multi-state operators deduct standard business costs, improving free cash flow and potentially reshaping wholesale pricing strategy across compliant markets. Banking access would likely improve too, though federal illegality under any Schedule III classification wouldn't disappear entirely - cashless payment friction at dispensary POS terminals isn't guaranteed to vanish overnight just because scheduling shifts.

Cresco Labs' newly secured $50 million revolving credit facility from Needham Bank is an early signal of where financing is headed: non-dilutive capital aimed at acquisitions and positioning for a future senior-exchange listing. Expect more multi-state operators to pursue similar credit arrangements as lenders grow comfortable with cannabis collateral.

Reading the Upside Numbers With Some Caution

Analyst price targets compiled across MSOS holdings show wide dispersion. Verano carries the steepest projected upside at roughly 195%, followed by Jushi Holdings near 183% and Cresco Labs close to 99%. Among the larger holdings, Green Thumb Industries stands out with about 70% upside, notably higher than Trulieve or Curaleaf despite Trulieve's outsized weighting and market attention.

To put it plainly: bigger upside numbers usually reflect smaller market capitalizations and higher volatility, not necessarily stronger fundamentals. Retail sentiment on platforms like Stocktwits currently runs "extremely bullish" for MSOS, Trulieve and Green Thumb, but enthusiasm on social trading forums is not a substitute for reviewing audited financials, lab testing compliance records, or state-by-state licensing exposure before drawing conclusions about any single operator's prospects.

Why Operators Should Watch the Regulatory Calendar Closely

For dispensary owners and wholesale suppliers who aren't publicly traded, this rally is still relevant. Capital markets sentiment shapes valuations used in acquisition talks, lending terms offered by regional banks, and even landlord willingness to sign leases with cannabis tenants. A favorable Schedule III outcome in July could accelerate consolidation as better-capitalized multi-state operators go shopping for licenses in newly opened medical markets. A delayed or narrower ruling could just as easily cool the current enthusiasm fast. Either way, the June 29 hearing deserves more attention from operators than the ETF price charts do.